Teijin Pharma Releases SAS Testing Device.Tokyo, Japan, Aug 21, 2006 - (JCN JCN Japan Corporate News JCN Journal of Cognitive Neuroscience JCN Journal of Cardiovascular Nursing JCN Journal of Christian Nursing JCN Job Control Number JCN Journal of Child Neurology JCN joint communications network (US DoD) ) - Teijin Pharma released the SAS-2100, a device to test and screen sleep apnea syndrome sleep apnea syndrome Ondine's curse A condition defined by frequent episodes of sleep apnea, hypopnea, and Sx of functional respiratory impairment; it is potentially life-threatening, and associated with daytime hypersomnolence, MVAs, and cardiovascular M&M in (SAS (1) (SAS Institute Inc., Cary, NC, www.sas.com) A software company that specializes in data warehousing and decision support software based on the SAS System. Founded in 1976, SAS is one of the world's largest privately held software companies. See SAS System. ) at home, on August 21. Used with a wristband weighing only 100g, the device can detect whether or not there is apnea, and if any, its intensity, without technical, all-night testing of electroencephalogram electroencephalogram /elec·tro·en·ceph·a·lo·gram/ (EEG) (-en-sef´ah-lo-gram?) a recording of the potentials on the skull generated by currents emanating spontaneously from nerve cells in the brain, with fluctuations in potential seen as at hospital. With the device, a suspected SAS patient can record his/her respiratory conditions while sleeping, and medical institutions can download those data to PCs for analysis using dedicated software. The price is set at 775,000 yen. Copyright [c] 2006 Japan Corporate News Network. All rights reserved. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion